News

During an Oncology Town Hall™ virtual meeting, 4 investigators in multiple myeloma addressed emerging therapies, optimal sequencing, the role of minimal residual disease to inform therapy, and the possibility of storing T cells for use in later CAR T-cell therapy.

According to Manali Bhave, MD, neratinib plus fulvestrant plus trastuzumab and should be considered as a therapeutic option with clinically meaningful benefit in patients with HER2-mutant metastatic breast cancer.

According to Marcia Brose, MD, PhD, FASCO, interim findings from the phase 3 LIBRETTO-531 trial confirms the benefit of selpercatinib in patients with advanced, RET-mutant medullary thyroid cancer.

The DeLLphi-300 trial of a bispecific T-cell engager showed favorable outcomes in patients with previously treated small cell lung cancer.

The metastasis-free survival benefit of enzalutamide, and other efficacy and safety data are now under FDA review for the potential approval of the drug for patients with non-metastatic castration-sensitive prostate cancer.

Lisocabtagene maraleucel showed activity in patients with relapsed/refractory mantle cell lymphoma, according to findings from the TRANSCEND-NHL-001 study.

In an interview with Targeted Oncology, Daniel P. Petrylak, MD, discussed findings from the TROPHY-U-01 study for patients with mUC, and what the next steps for research are.

On the heels of promising findings from the phase 3 IMerge study, the FDA has accepted the new drug application of imetelstat for transfusion-dependent anemia in patients with lower-risk MDS.

The combination of ibrutinib with chemoimmunotherapy improved the duration of response for a subset of patients with relapsed follicular lymphoma and marginal zone lymphoma.

A primary end point has been met in the phase 3 CONTACT-02 clinical trial.

In an interview with Targeted Oncology, Bradley A. McGregor, MD, discussed the main takeaways from a phase 3 study of cabozantinib, nivolumab, and ipilimumab for patients with renal cell carcinoma with variant histologies.

A pause on trials of magrolimab in acute myeloid leukemia will affect the screening and enrollment of patients.

Treatment with liso-cel had a manageable safety profile with no new safety signals in patients with relapsed/ refractory follicular lymphoma.

According to investigators of the phase 3 COLUMBUS study, BRAF/MEK inhibitor combinations are better with more BRAF inhibition.

Fadraciclib, a highly selective inhibitor of CDK2 and CDK9, is being investigated in clinical trials for patients with solid tumors and hematologic malignancies.

In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the implications of findings from the phase 1 study assessing olaparib and high-dose chemotherapy in patients with relapsed/refractory lymphomas.

Ziftomenib showed safety and efficacy in heavily pretreated patients with comutations and NPM1-mutated, relapsed/refractory acute myeloid leukemia.

According to Eric Jonasch, MD, promising findings from LITESPARK-005 may help with a goal of getting belzutifan FDA approval for patients with refractory renal cell carcinoma.

In an interview, Shilpa Gupta, MD, discussed findings from cohort A of Study EV-103 in patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.

A number of trials evaluating rintatolimod as a combinational therapy for a wide range of solid tumor types are underway and planned, including in pancreatic and breast cancer.

In an interview with Targeted Oncology, Se-Hoon Lee, MD, highlights the results of the long-term analysis of the CHRYSALIS trial looking at amivantamab and lazertinib for patients with EGFR mutated non–small cell lung cancer.

For patients who are ineligible for erythropoiesis-stimulating agents, luspatercept-aamt offers a new approach.

Data from HER2CLIMB-02 will be presented at an upcoming medical meeting and the results will be shared with the FDA.

Guillermo Garcia-Manero, MD, discussed 2 studies evaluating therapies for patients with lower-risk myelodysplastic syndrome.

In an 8-year follow up analysis of patients on the ExteNET trial, researchers saw that overall survival was not significantly different to rates on placebo.

Rohan Garje, MD, explains some of the differences between the sarcomatoid and classic carcinoma of the bladder.

Several immunotherapies are now approved for the management of metastatic RCC. However, immunotherapy-based combination regimens are associated with high rates of treatment-related toxicities and do not yield objective responses in a significant proportion of patients.

Daniel P. Petrylak, MD, highlights data from the phase 3 KEYNOTE-921 of pembrolizumab in combination with docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer.

Currently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.